Literature DB >> 17287951

Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations.

Piotr Kozlowski1, Penelope Roberts, Sandra Dabora, David Franz, John Bissler, Hope Northrup, Kit Sing Au, Ross Lazarus, Dorota Domanska-Pakiela, Katarzyna Kotulska, Sergiusz Jozwiak, David J Kwiatkowski.   

Abstract

Tuberous sclerosis (TSC) is an autosomal dominant disorder caused by mutations in either of two genes, TSC1 and TSC2. Point mutations and small indels account for most TSC1 and TSC2 mutations. We examined 261 TSC DNA samples (209 small-mutation-negative and 52 unscreened) for large deletion/duplication mutations using multiplex ligation-dependent probe amplification (MLPA) probe sets designed to permit interrogation of all TSC1/2 exons, as well as 15-50 kb of flanking sequence. Large deletion/duplication mutations in TSC1 and TSC2 were identified in 54 patients, of which 50 were in TSC2, and 4 were in TSC1. All but two mutations were deletions. Only 13 deletions were intragenic in TSC2, and one in TSC1, so that 39 (73%) deletions extended beyond the 5', 3' or both ends of TSC1 or TSC2. Mutations were identified in 24% of small-mutation-negative and 8% of unscreened samples. Eight of 54 (15%) mutations were mosaic, affecting 34-62% of cells. All intragenic mutations were confirmed by LR-PCR. Genotype/phenotype analysis showed that all (21 of 21) patients with TSC2 deletions extending 3' into the PKD1 gene had kidney cysts. Breakpoints of intragenic deletions were randomly distributed along the TSC2 sequence, and did not preferentially involve repeat sequence elements. Our own 20-plex probe sets gave more robust performance than the 40-plex probe sets from MRC-Holland. We conclude that large deletions in TSC1 and TSC2 account for about 0.5 and 6% of mutations seen in TSC patients, respectively, and MLPA is a highly sensitive and accurate detection method, including for mosaicism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17287951     DOI: 10.1007/s00439-006-0308-9

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  24 in total

1.  MaskerAid: a performance enhancement to RepeatMasker.

Authors:  J A Bedell; I Korf; W Gish
Journal:  Bioinformatics       Date:  2000-11       Impact factor: 6.937

2.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.

Authors:  Jan P Schouten; Cathal J McElgunn; Raymond Waaijer; Danny Zwijnenburg; Filip Diepvens; Gerard Pals
Journal:  Nucleic Acids Res       Date:  2002-06-15       Impact factor: 16.971

3.  Gross genomic rearrangements involving deletions in the CFTR gene: characterization of six new events from a large cohort of hitherto unidentified cystic fibrosis chromosomes and meta-analysis of the underlying mechanisms.

Authors:  Claude Férec; Teresa Casals; Nadia Chuzhanova; Milan Macek; Thierry Bienvenu; Andrea Holubova; Caitriona King; Trudi McDevitt; Carlo Castellani; Philip M Farrell; Molly Sheridan; Sarah-Jane Pantaleo; Ourida Loumi; Taieb Messaoud; Harry Cuppens; Francesca Torricelli; Garry R Cutting; Robert Williamson; Maria Jesus Alonso Ramos; Pier Franco Pignatti; Odile Raguénès; David N Cooper; Marie-Pierre Audrézet; Jian-Min Chen
Journal:  Eur J Hum Genet       Date:  2006-05       Impact factor: 4.246

Review 4.  Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis.

Authors:  A C Jones; M M Shyamsundar; M W Thomas; J Maynard; S Idziaszczyk; S Tomkins; J R Sampson; J P Cheadle
Journal:  Am J Hum Genet       Date:  1999-05       Impact factor: 11.025

5.  Renal disease in adults with TSC2/PKD1 contiguous gene syndrome.

Authors:  Guido Martignoni; Franco Bonetti; Maurizio Pea; Regina Tardanico; Matteo Brunelli; John N Eble
Journal:  Am J Surg Pathol       Date:  2002-02       Impact factor: 6.394

6.  Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.

Authors:  S L Dabora; S Jozwiak; D N Franz; P S Roberts; A Nieto; J Chung; Y S Choy; M P Reeve; E Thiele; J C Egelhoff; J Kasprzyk-Obara; D Domanska-Pakiela; D J Kwiatkowski
Journal:  Am J Hum Genet       Date:  2000-12-08       Impact factor: 11.025

7.  PKD1 intron 21: triplex DNA formation and effect on replication.

Authors:  Hiren P Patel; Lu Lu; Richard T Blaszak; John J Bissler
Journal:  Nucleic Acids Res       Date:  2004-02-27       Impact factor: 16.971

8.  TSC1 and TSC2 mutations in tuberous sclerosis, the associated phenotypes and a model to explain observed TSC1/ TSC2 frequency ratios.

Authors:  Nicola Langkau; Nicola Martin; Regine Brandt; Karin Zügge; Stefanie Quast; Gerd Wiegele; Anna Jauch; Marion Rehm; Andrea Kuhl; Monika Mack-Vetter; Lothar Bernd Zimmerhackl; Bart Janssen
Journal:  Eur J Pediatr       Date:  2002-06-08       Impact factor: 3.183

9.  Identification and characterization of the tuberous sclerosis gene on chromosome 16.

Authors: 
Journal:  Cell       Date:  1993-12-31       Impact factor: 41.582

10.  TSC1 and TSC2 deletions differ in size, preference for recombinatorial sequences, and location within the gene.

Authors:  L Longa; A Saluto; A Brusco; S Polidoro; S Padovan; A Allavena; C Carbonara; E Grosso; N Migone
Journal:  Hum Genet       Date:  2001-02       Impact factor: 4.132

View more
  65 in total

1.  Custom-designed MLPA using multiple short synthetic probes: application to methylation analysis of five promoter CpG islands in tumor and urine specimens from patients with bladder cancer.

Authors:  Reza R Serizawa; Ulrik Ralfkiaer; Christina Dahl; Gitte W Lam; Alastair B Hansen; Kenneth Steven; Thomas Horn; Per Guldberg
Journal:  J Mol Diagn       Date:  2010-04-22       Impact factor: 5.568

2.  Characterisation of TSC1 promoter deletions in tuberous sclerosis complex patients.

Authors:  Ans M W van den Ouweland; Peter Elfferich; Bernard A Zonnenberg; Willem F Arts; Tjitske Kleefstra; Mark D Nellist; Jose M Millan; Caroline Withagen-Hermans; Anneke J A Maat-Kievit; Dicky J J Halley
Journal:  Eur J Hum Genet       Date:  2010-09-29       Impact factor: 4.246

3.  Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease.

Authors:  Katharina Hopp; Emilie Cornec-Le Gall; Sarah R Senum; Iris B A W Te Paske; Sonam Raj; Sravanthi Lavu; Saurabh Baheti; Marie E Edwards; Charles D Madsen; Christina M Heyer; Albert C M Ong; Kyongtae T Bae; Richard Fatica; Theodore I Steinman; Arlene B Chapman; Berenice Gitomer; Ronald D Perrone; Frederic F Rahbari-Oskoui; Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2019-10-09       Impact factor: 10.612

4.  Multiplex ligation-depending probe amplification is not suitable for detection of low-grade mosaicism.

Authors:  Monique M van Veghel-Plandsoen; Cokkie H Wouters; Joan N R Kromosoeto; Mariska C den Ridder-Klünnen; Dicky J J Halley; Ans M W van den Ouweland
Journal:  Eur J Hum Genet       Date:  2011-04-13       Impact factor: 4.246

5.  [Two novel TSC2 frameshift mutations in tuberous sclerosis complex].

Authors:  Yu-Chun Pan; Wei-Qing Wu; Jian-Sheng Xie; Cai-Qun Luo; Ying Hao
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-03

6.  Genotype and brain pathology phenotype in children with tuberous sclerosis complex.

Authors:  Iris E Overwater; Rob Swenker; Emma L van der Ende; Kimberley Bm Hanemaayer; Marianne Hoogeveen-Westerveld; Agnies M van Eeghen; Maarten H Lequin; Ans Mw van den Ouweland; Henriëtte A Moll; Mark Nellist; Marie-Claire Y de Wit
Journal:  Eur J Hum Genet       Date:  2016-07-13       Impact factor: 4.246

7.  Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome.

Authors:  Mark B Consugar; Wai C Wong; Patrick A Lundquist; Sandro Rossetti; Vickie J Kubly; Denise L Walker; Laureano J Rangel; Richard Aspinwall; W Patrick Niaudet; Seza Ozen; Albert David; Milen Velinov; Eric J Bergstralh; Kyongtae T Bae; Arlene B Chapman; Lisa M Guay-Woodford; Jared J Grantham; Vicente E Torres; Julian R Sampson; Brian D Dawson; Peter C Harris
Journal:  Kidney Int       Date:  2008-09-24       Impact factor: 10.612

8.  Copy number variations and cancer.

Authors:  Adam Shlien; David Malkin
Journal:  Genome Med       Date:  2009-06-16       Impact factor: 11.117

9.  Rapid high-throughput analysis of DNaseI hypersensitive sites using a modified Multiplex Ligation-dependent Probe Amplification approach.

Authors:  Thomas Ohnesorg; Stefanie Eggers; Wouter N Leonhard; Andrew H Sinclair; Stefan J White
Journal:  BMC Genomics       Date:  2009-09-04       Impact factor: 3.969

10.  TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.

Authors:  M-C Liang; J Ma; L Chen; P Kozlowski; W Qin; D Li; J Goto; T Shimamura; D N Hayes; M Meyerson; D J Kwiatkowski; K-K Wong
Journal:  Oncogene       Date:  2009-12-07       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.